申请人:Sterling Drug Inc.
公开号:US03992380A1
公开(公告)日:1976-11-16
Antibacterial 5,8-dihydro-8-(lower-alkyl)-5-oxo-2-Q-4-R.sub.2 -6-Z-pyrido[2,3-d]pyrimidine (I) where Z is carboxy or lower-carbalkoxy, R.sub.2 is hydrogen or lower-alkyl and Q is 4(or 3)-pyridinyl or 4(or 3)-pyridinyl having one or two lower-alkyl substituents is prepared by heating di-(lower-alkyl) N-(2-Q-6-R.sub.2 -4-pyrimidinyl)aminomethylenemalonate (III) to produce 5,8-dihydro-5-oxo-2-Q-4-R.sub.2 -6-Z-pyrido[2,3-d]pyrimidine (II) which is tautomeric with 5-hydroxy-2-Q-4-R.sub.2 -6-Z-pyrido[2,3-d]pyrimidine (IIA) where Q and R.sub.2 are the same as in I above and Z is lower-carbalkoxy, reacting II(or IIA) with a lower-alkylating agent to produce I where Z is lower-carbalkoxy and hydrolyzing this ester (I) to produce I where Z is carboxy. Alternatively, the acid (II or IIA where Z is COOH) can be alkylated after first hydrolyzing the ester (II or IIA where Z is lower-carbalkoxy). The preparations of the intermediate III and intermediates used in its preparation are given.
抗菌性5,8-二氢-8-(较低烷基)-5-氧代-2-Q-4-R.sub.2-6-Z-吡啶并[2,3-d]嘧啶(I),其中Z为羧基或较低羧烷氧基,R.sub.2为氢或较低烷基,Q为4(或3)-吡啶基或带有一个或两个较低烷基取代基的4(或3)-吡啶基,通过加热二-(较低烷基)N-(2-Q-6-R.sub.2-4-嘧啶基)氨甲亚甲基丙二酸酯(III)制备,以产生5,8-二氢-5-氧代-2-Q-4-R.sub.2-6-Z-吡啶并[2,3-d]嘧啶(II),其与5-羟基-2-Q-4-R.sub.2-6-Z-吡啶并[2,3-d]嘧啶(IIA)互变异构,其中Q和R.sub.2与上述I中相同,Z为较低羧烷氧基,将II(或IIA)与较低烷基化试剂反应以产生I,其中Z为较低羧烷氧基,并水解此酯(I)以产生Z为羧基的I。或者,酸(II或IIA,其中Z为COOH)在首先水解酯(II或IIA,其中Z为较低羧烷氧基)后可以被烷基化。给出了中间体III及其制备中使用的中间体的制备方法。